胆管上皮细胞
胆管
原发性硬化性胆管炎
再生(生物学)
纤维化
肝内胆管
胆管疾病
癌症研究
调节性T细胞
转基因小鼠
转基因
T细胞
渗透(HVAC)
免疫学
受体
表型
信号转导
医学
胆道
生物
化学
原发性胆汁性肝硬化
细胞疗法
病理
导管(解剖学)
作者
Naruhiro Kimura,Man Chun Wong,Ben Higgins,Gareth R. Hardisty,Pei-Chi Huang,Matamoana Muller,Maxym Besh,Daniel A. Patten,Timothy James Kendall,Prakash Ramachandran,Adriano Giorgio Rossi,Graham Anderson,Shishir Shetty,David R. Withers,Atsunori Tsuchiya,Shuji Terai,Wei‐Yu Lu
出处
期刊:Cell Reports
[Cell Press]
日期:2025-11-01
卷期号:44 (11): 116557-116557
被引量:4
标识
DOI:10.1016/j.celrep.2025.116557
摘要
Cholangiopathies such as primary sclerosing cholangitis (PSC) cause damage to the bile ducts with no effective cure. Reduction and impairment in the function of regulatory T cells (Tregs) occur in PSC. We investigate whether Tregs regulate bile duct regeneration and the dynamics of Treg turnover during bile duct injury. We use the transgenic Foxp3 GFPDTR model to mimic reduced Treg infiltration in PSC and show that Tregs mediate cholangiocyte response to biliary injury. Fate mapping of Tregs reveals that intrahepatic Tregs acquire a pro-inflammatory phenotype, even after interleukin-2 (IL-2)-mediated Treg expansion. Ox40L expression correlates with fibrosis in PSC patients. Enhancing Treg numbers through IL-2 complex administration and blocking Ox40 signaling simultaneously suppresses the inflammatory phenotype of Tregs and reduces bile duct damage and fibrosis. We demonstrate that bile duct regeneration can be enhanced by combining Treg-based therapy and targeting co-stimulatory molecules, such as Ox40L.
科研通智能强力驱动
Strongly Powered by AbleSci AI